We are analyzing https://link.springer.com/article/10.1007/s13539-010-0002-6.

Title:
Cachexia as a major underestimated and unmet medical need: facts and numbers | Journal of Cachexia, Sarcopenia and Muscle
Description:
Cachexia is a serious, however underestimated and underrecognised medical consequence of malignant cancer, chronic heart failure (CHF), chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), cystic fibrosis, rheumatoid arthritis, Alzheimer
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Fitness & Wellness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure if the website is profiting.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

cachexia, article, weight, google, scholar, loss, pubmed, cancer, chronic, patients, muscle, cas, body, anker, prevalence, clinical, journal, disease, copd, rheumatoid, definition, heart, arthritis, diseases, sarcopenia, haehling, cardiac, problem, research, medical, chf, wasting, table, access, pulmonary, illnesses, privacy, cookies, data, information, publish, open, failure, ckd, population, due, terms, treatment, therapies, fat,

Topics {✒️}

angiotensin-converting-enzyme inhibitors anabolic–catabolic dysbalance exists stephan von haehling article download pdf privacy choices/manage cookies health care professionals open access license poole-wilson pa regional oncology centre cancer anorexia-cachexia syndrome small sample size chronic heart failure pulmonary cachexia syndrome proc nutr soc final common pathway cosmic study group european economic area previous 3–12 months combined poor-symptom status nat rev cancer von haehling webb-peploe km atheroprotective natural antibodies tumor necrosis factor irccs san raffaele comparing study results cross-sectional study charité medical school conditions privacy policy rev respir dis anti-catabolic therapies chronic kidney disease campus virchow-klinikum lean body mass fat-free mass involuntary weight loss arthritis res ther accepting optional cookies open access commencing radiotherapy treatment resectable pancreatic cancer independent risk factor underrecognised medical problem fat tissue appears increased fat mass 'copyright information' section progressive weight loss edematous weight loss frequent cachexia subtypes cachexia worsens prognosis

Questions {❓}

1 Why a new journal?
2 What is cachexia?
Given the fact that cachexia has been known for such a long time, why do we think that the time is ripe to publish a new journal, the Journal of Cachexia, Sarcopenia and Muscle?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Cachexia as a major underestimated and unmet medical need: facts and numbers
         description:Cachexia is a serious, however underestimated and underrecognised medical consequence of malignant cancer, chronic heart failure (CHF), chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), cystic fibrosis, rheumatoid arthritis, Alzheimer's disease, infectious diseases, and many other chronic illnesses. The prevalence of cachexia is high, ranging from 5% to 15% in CHF or COPD to 60% to 80% in advanced cancer. By population prevalence, the most frequent cachexia subtypes are in order: COPD cachexia, cardiac cachexia (in CHF), cancer cachexia, and CKD cachexia. In industrialized countries (North America, Europe, Japan), the overall prevalence of cachexia (due to any disease) is growing and currently about 1%, i.e., about nine million patients. The relative prevalence of cachexia is somewhat less in Asia, but is a growing problem there as well. In absolute terms, cachexia is, in Asia (due to the larger population), as least as big a problem as in the Western world. Cachexia is also a big medical problem in South America and Africa, but data are scarce. A consensus statement recently proposed to diagnose cachexia in chronic diseases when there is weight loss exceeding 5% within the previous 3–12 months combined with symptoms characteristic for cachexia (e.g., fatigue), loss of skeletal muscle and biochemical abnormalities (e.g., anemia or inflammation). Treatment approaches using anabolics, anti-catabolic therapies, appetite stimulants, and nutritional interventions are under development. A more thorough understanding of the pathophysiology of cachexia development and progression is needed that likely will lead to combination therapies being developed. These efforts are greatly needed as presence of cachexia is always associated with high-mortality and poor-symptom status and dismal quality of life. It is thought that in cancer, more than 30% of patients die due to cachexia and more than 50% of patients with cancer die with cachexia being present. In other chronic illnesses, one can estimate that up to 30% of patients die with some degree of cachexia being present. Mortality rates of patients with cachexia range from 10% to 15% per year (COPD), to 20% to 30% per year (CHF, CKD) to 80% in cancer.
         datePublished:2010-10-26T00:00:00Z
         dateModified:2010-10-26T00:00:00Z
         pageStart:1
         pageEnd:5
         license:https://creativecommons.org/licenses/by-nc/2.0
         sameAs:https://doi.org/10.1007/s13539-010-0002-6
         keywords:
            Internal Medicine
            Oncology
            Geriatrics/Gerontology
            Clinical Nutrition
            Molecular Medicine
            Pharmacology/Toxicology
         image:
         isPartOf:
            name:Journal of Cachexia, Sarcopenia and Muscle
            issn:
               2190-6009
               2190-5991
            volumeNumber:1
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Stephan von Haehling
               affiliation:
                     name:Charité Medical School, Campus Virchow-Klinikum
                     address:
                        name:Applied Cachexia Research, Department of Cardiology, Charité Medical School, Campus Virchow-Klinikum, Berlin, Germany
                        type:PostalAddress
                     type:Organization
                     name:Charité Medical School, Campus Mitte
                     address:
                        name:Center for Cardiovascular Research (CCR), Charité Medical School, Campus Mitte, Berlin, Germany
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Stefan D. Anker
               affiliation:
                     name:Charité Medical School, Campus Virchow-Klinikum
                     address:
                        name:Applied Cachexia Research, Department of Cardiology, Charité Medical School, Campus Virchow-Klinikum, Berlin, Germany
                        type:PostalAddress
                     type:Organization
                     name:Centre for Clinical and Basic Research, IRCCS San Raffaele
                     address:
                        name:Centre for Clinical and Basic Research, IRCCS San Raffaele, Rome, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Cachexia as a major underestimated and unmet medical need: facts and numbers
      description:Cachexia is a serious, however underestimated and underrecognised medical consequence of malignant cancer, chronic heart failure (CHF), chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), cystic fibrosis, rheumatoid arthritis, Alzheimer's disease, infectious diseases, and many other chronic illnesses. The prevalence of cachexia is high, ranging from 5% to 15% in CHF or COPD to 60% to 80% in advanced cancer. By population prevalence, the most frequent cachexia subtypes are in order: COPD cachexia, cardiac cachexia (in CHF), cancer cachexia, and CKD cachexia. In industrialized countries (North America, Europe, Japan), the overall prevalence of cachexia (due to any disease) is growing and currently about 1%, i.e., about nine million patients. The relative prevalence of cachexia is somewhat less in Asia, but is a growing problem there as well. In absolute terms, cachexia is, in Asia (due to the larger population), as least as big a problem as in the Western world. Cachexia is also a big medical problem in South America and Africa, but data are scarce. A consensus statement recently proposed to diagnose cachexia in chronic diseases when there is weight loss exceeding 5% within the previous 3–12 months combined with symptoms characteristic for cachexia (e.g., fatigue), loss of skeletal muscle and biochemical abnormalities (e.g., anemia or inflammation). Treatment approaches using anabolics, anti-catabolic therapies, appetite stimulants, and nutritional interventions are under development. A more thorough understanding of the pathophysiology of cachexia development and progression is needed that likely will lead to combination therapies being developed. These efforts are greatly needed as presence of cachexia is always associated with high-mortality and poor-symptom status and dismal quality of life. It is thought that in cancer, more than 30% of patients die due to cachexia and more than 50% of patients with cancer die with cachexia being present. In other chronic illnesses, one can estimate that up to 30% of patients die with some degree of cachexia being present. Mortality rates of patients with cachexia range from 10% to 15% per year (COPD), to 20% to 30% per year (CHF, CKD) to 80% in cancer.
      datePublished:2010-10-26T00:00:00Z
      dateModified:2010-10-26T00:00:00Z
      pageStart:1
      pageEnd:5
      license:https://creativecommons.org/licenses/by-nc/2.0
      sameAs:https://doi.org/10.1007/s13539-010-0002-6
      keywords:
         Internal Medicine
         Oncology
         Geriatrics/Gerontology
         Clinical Nutrition
         Molecular Medicine
         Pharmacology/Toxicology
      image:
      isPartOf:
         name:Journal of Cachexia, Sarcopenia and Muscle
         issn:
            2190-6009
            2190-5991
         volumeNumber:1
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Stephan von Haehling
            affiliation:
                  name:Charité Medical School, Campus Virchow-Klinikum
                  address:
                     name:Applied Cachexia Research, Department of Cardiology, Charité Medical School, Campus Virchow-Klinikum, Berlin, Germany
                     type:PostalAddress
                  type:Organization
                  name:Charité Medical School, Campus Mitte
                  address:
                     name:Center for Cardiovascular Research (CCR), Charité Medical School, Campus Mitte, Berlin, Germany
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Stefan D. Anker
            affiliation:
                  name:Charité Medical School, Campus Virchow-Klinikum
                  address:
                     name:Applied Cachexia Research, Department of Cardiology, Charité Medical School, Campus Virchow-Klinikum, Berlin, Germany
                     type:PostalAddress
                  type:Organization
                  name:Centre for Clinical and Basic Research, IRCCS San Raffaele
                  address:
                     name:Centre for Clinical and Basic Research, IRCCS San Raffaele, Rome, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Journal of Cachexia, Sarcopenia and Muscle
      issn:
         2190-6009
         2190-5991
      volumeNumber:1
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Charité Medical School, Campus Virchow-Klinikum
      address:
         name:Applied Cachexia Research, Department of Cardiology, Charité Medical School, Campus Virchow-Klinikum, Berlin, Germany
         type:PostalAddress
      name:Charité Medical School, Campus Mitte
      address:
         name:Center for Cardiovascular Research (CCR), Charité Medical School, Campus Mitte, Berlin, Germany
         type:PostalAddress
      name:Charité Medical School, Campus Virchow-Klinikum
      address:
         name:Applied Cachexia Research, Department of Cardiology, Charité Medical School, Campus Virchow-Klinikum, Berlin, Germany
         type:PostalAddress
      name:Centre for Clinical and Basic Research, IRCCS San Raffaele
      address:
         name:Centre for Clinical and Basic Research, IRCCS San Raffaele, Rome, Italy
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Stephan von Haehling
      affiliation:
            name:Charité Medical School, Campus Virchow-Klinikum
            address:
               name:Applied Cachexia Research, Department of Cardiology, Charité Medical School, Campus Virchow-Klinikum, Berlin, Germany
               type:PostalAddress
            type:Organization
            name:Charité Medical School, Campus Mitte
            address:
               name:Center for Cardiovascular Research (CCR), Charité Medical School, Campus Mitte, Berlin, Germany
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Stefan D. Anker
      affiliation:
            name:Charité Medical School, Campus Virchow-Klinikum
            address:
               name:Applied Cachexia Research, Department of Cardiology, Charité Medical School, Campus Virchow-Klinikum, Berlin, Germany
               type:PostalAddress
            type:Organization
            name:Centre for Clinical and Basic Research, IRCCS San Raffaele
            address:
               name:Centre for Clinical and Basic Research, IRCCS San Raffaele, Rome, Italy
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Applied Cachexia Research, Department of Cardiology, Charité Medical School, Campus Virchow-Klinikum, Berlin, Germany
      name:Center for Cardiovascular Research (CCR), Charité Medical School, Campus Mitte, Berlin, Germany
      name:Applied Cachexia Research, Department of Cardiology, Charité Medical School, Campus Virchow-Klinikum, Berlin, Germany
      name:Centre for Clinical and Basic Research, IRCCS San Raffaele, Rome, Italy

External Links {🔗}(96)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.12s.

LINK . SPRINGER . COM {}